Biolight

Biolight (宝莱特) is presented in the supplied evidence as a commercial brand in the medical-device and medtech field. The evidence also associates it with surgical devices, but does not identify particular products, product lines, or clinical specialties. The supplied website is https://www.blt.com.cn. Beyond the brand name and its broad medical-device context, the available evidence does not establish the company’s legal identity, founding history, headquarters, ownership, leadership, markets, or current operating status. Those details are therefore left unspecified rather than inferred from the name or from unrelated namesakes.

The supplied evidence does not document Biolight’s founding, early development, corporate structure, or dated milestones. It identifies the subject only in broad terms as a medical-device and medtech brand, with a reference to surgical devices. The supplied website provides an official web address, but no site content was included as evidence here. Consequently, a detailed corporate history cannot be responsibly established from the available material, and no dates, founders, transactions, or leadership changes are asserted.

• Biolight (宝莱特) is a Chinese medical device brand active in the medical device, medtech and surgical device segments.

The available evidence places Biolight in the medical-device and medtech category, including a reference to surgical devices; it does not establish a more specific market position.

• Medical devices

  The supplied evidence associates the brand with medical devices but does not specify product models or categories.

• Surgical devices

  Surgical devices are mentioned in the supplied evidence; no further product details are given.

• 2023

  Incomplete Consolidation, Inaccurate Accounting: Biolight Warned Twice by Regulator in Two Years

  In 2023, the Guangdong Securities Regulatory Bureau found that Biolight’s consolidated financial statement scope was incomplete and its 2022 performance forecast disclosure was inaccurate, and issued warning letters to the company, chairman Yan Jinyuan, general manager Liao Wei, CFO Xu Wei and board secretary Yang Yongxing. In 2024, it identified five issues—revenue recognition, sales returns, conversion of construction in progress to fixed assets, goodwill impairment testing and non-compliant internal control—and again issued warning letters to the company, Yan Jinyuan and Xu Wei. The warning letters were recorded in integrity files, and rectification and internal accountability were required.

  Source

Read more

1. 1Official website supplied in subject recordblt.com.cn
2. 2Incomplete Consolidation, Inaccurate Accounting: Biolight Warned Twice by Regulator in Two Yearscsrc.gov.cn
3. 3Incomplete Consolidation, Inaccurate Accounting: Biolight Warned Twice by Regulator in Two Yearscsrc.gov.cn
4. 4Incomplete Consolidation, Inaccurate Accounting: Biolight Warned Twice by Regulator in Two Yearsm.ce.cn